Briacell Therap (NASDAQ:BCTX) Releases Earnings Results

Briacell Therap (NASDAQ:BCTX) announced its quarterly earnings data on Tuesday. The company reported ($2.58) earnings per share for the quarter, Zacks reports.

Briacell Therap Trading Up 7.2%

Briacell Therap stock traded up $0.28 during mid-day trading on Wednesday, reaching $4.09. The company had a trading volume of 53,630 shares, compared to its average volume of 569,155. Briacell Therap has a fifty-two week low of $3.60 and a fifty-two week high of $98.20. The company has a market cap of $29.62 million, a P/E ratio of -0.09 and a beta of 1.46. The business has a fifty day simple moving average of $4.87 and a 200 day simple moving average of $8.20.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Briacell Therap presently has a consensus rating of “Hold” and an average target price of $320.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC acquired a new stake in shares of Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is currently owned by institutional investors.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.